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Abstract  
The BCR-ABL tyrosine kinase inhibitor Imatinib is highly effective for chronic myeloid leukemia 
(CML). However, some patients gradually develop resistance to Imatinib, resulting in therapeutic failure. 
In the present study, we analyzed 192 CML patients, from which CML relapse was observed in 17 
individuals with involvement of other chromosomes in addition to Philadelphia translocation and who 
were on treatment of Imatinib (400mg per day since last 3-4 years).  Interestingly, all 17 individuals 
had only BCR/ABL fusion at the time of diagnosis and attained complete Cytogenetic and hematological 
remission (CHR) within 18 weeks of the therapy.  Three individuals among these 17 were not regular in 
the uptake of Imatinib after attaining CHR and CCyR and could be probable reason for relapse.  In 
addition, we have also recorded primary resistance to Imatinib in 4 individuals who were diagnosed with 
some complex chromosomal variants.  Therefore, either involvement of other genes along with 
BCR/ABL fusion, or additional chromosomes and point mutation in the fusion BCR/ABL gene itself 
could be a reason for primary resistance and relapse to Imatinib. 
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Introduction 
Chronic Myeloid Leukemia (CML) is attributed to the chromosomal translocation t(9;22)(q34; q11), 
yielding the Philadelphia (Ph) chromosome. This translocation generates a fusion gene that encodes 
BCR-ABL, an active protein tyrosine kinase gene. The resulting BCR-ABL (breakpoint cluster 
region-Abelson) fusion protein is a constitutively active tyrosine kinase, conferring enhanced proliferative 
activity and decreased sensitivity to apoptotic cell death in the cells in which it is expressed.  
Imatinib (Gleevec, formerly STI571; Novartis Pharmaceuticals) is a 2-phenylaminopyramidine 
compound that is a potent inhibitor of all ABL tyrosine kinases (c-ABL, BCR-ABL, and Tel/ABL). In 
addition, Imatinib is an inhibitor of the tyrosine kinases of the platelet-derived growth factor (PDGF) 
receptor [1], , ARG [2], and c-Kit, and the macrophage colony-stimulating receptor, c-fms.  
Clinical trials have demonstrated the efficacy of Imatinib in chronic-phase CML[3]. Approximately 95% 
of patients with de novo chronic-phase CML achieve complete hematologic response, while 90% achieve 
major, and 80% complete, cytogenetic remissions. It is effective as a single agent in the treatment of CML 
patients, with the most encouraging results seen in patients in chronic phase (CP) disease.  
Although Imatinib is widely recognized as the standard of care in the first-line treatment of chronic 
myeloid leukemia (CML); however, resistance can limit its long-term benefits. Early identification of 
the loss of response to Imatinib is therefore important for the optimal management of patients with this 
type of leukemia. Cytogenetic and molecular responses during the first 12 months of treatment have 
been shown to predict future responses (complete cytogenetic response and major molecular response) 
and reduce disease progression [4]. The degree of early reduction in BCR-ABL levels after 
commencing Imatinib therapy is a good indicator of subsequent response. Monitoring for kinase 
domain mutations should also be considered in patients with suboptimal response or in those who 
demonstrate resistance. Modification of the treatment strategy is required if there is a loss of response. 
Resistance to Imatinib can be categorized according to the time of onset: primary (intrinsic) 
resistance is a lack of efficacy from the onset of treatment with Imatinib and secondary (acquired) 
resistance (relapse) is defined as an initial response followed by a loss of efficacy with time of 
exposure to Imatinib. According to the clinical and laboratory criteria used for detection, resistance 
could be further subdivided into hematologic, cytogenetic, and molecular resistance.  
Materials and Methods 
Conventional cytogenetic analysis was performed on un-stimulated 24-hour culture of a bone marrow 
(BM)/Peripheral Blood specimen. The cells were cultured and processed by conventional methods, and the 
chromosomes were stained with Trypsin-Gyms Banding (GTG-banding). The karyotype was described 
according to the International System for Human Cytogenetic Nomenclature (ISCN, 2009) 
FISH was performed on uncultured bone marrow/blood cells by using BCR/ABL dual color dual fusion 
probes from Kreatech Diagnostics. Fluorescent signals were observed under Axio Scope A-1Microscope 
(Carl Zeiss, Germany) attached with Progress C-5 Camera. In manual investigation 200 cells were 
analyzed.  
Follow up was performed at every 3 to 6 month and Cytogenetic response to therapy was defined relative 
to the percentage of Ph+ metaphases identified by chromosome banding  analysis: complete if 0%, partial 
if from 1% to 34%, minor if from 35% to 95% and none if greater than 95%  Ph+ metaphases were 
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detected. 
Result and Discussion   
In the present study from 192 CML diagnosed individuals, we noticed that 21 individuals (4 at diagnosis, 
11- chronic phase and 6-accelerate phase) developed primary or secondary resistance to imatinib (Gleevec) 
while rest all have achieved CHR and CCyR. Out of 21 individuals, 17 were on imatinib treatment since 
last 3-4 years with a dose of 400mg/day.  At the time of diagnosis, all these 17 individuals had only 
BCR/ABL fusion;  t (9; 22)(q34; q11.2) and all had achieved 
 Real-time quantitative polymerase chain 
reaction (RT-qPCR) suggested  0.001% which indicates MMR [5,6]. At the 
molecular level, significant reduction in the level of BCR-ABL transcript has been measured by quantitative 
real-time PCR (RQ-PCR). CML relapse was observed in these 17 individuals along with extra chromosome 
i.e trisomy14, trisomy 17, trisomy 19, trisomy 21, iso(17q) and marker chromosome beside with BCR/ABL 
fusion in their follow up study (Fig.1a) (Table 1). The dose of Imatinib increased from 400mg/day to 
600mg/day in these 17 individuals, which also failed to achieve CHR and CCyR and MMolR. They have 
been switched on to second generation tyrosin kinase inhibitor (dasatinib/nilotinib). No further study was 
available for this individual weather this next generation Tyrosin kinase inhibitor helped to achieve 
remission or not. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 1a    52,XY,+Y,del(2p),+9,add(9q)t(9;22)(q34;q11.2)×2,+14,+17,+20,+22,der(22) t(9;22) 
(q34;q11.2)×2 
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         Figure 1b signal pattern: 4F1R1G: which suggest t (9; 22) X2 (additional Philadelphia chromosome) 
 
Table 1  Cytogenetic and hematological finding in CML Relapse patients. 
 
Sr 
no 
Age/sex Years on 
Imatinib 
Cytogenetic  relapse study Total WBC 
count/mm3 1 42/F 4 68,XXX, der(9)add (9q)X2,-17,iso(17)(q11.2) ,+der(22)del(22q)X2   22000/mm
3 
2 39/M 4 47,XY,+8,t(9;22)(q34;q12),iso(17q)  19000/mm3 
3 45/M 3 47,XY,+8,t(9;22)(q34;q12),iso(17q) 19500/mm3 
4 41/M 3.5 48,XY,+8, t(9;22)(q34;q11),iso (17)(q),+21  21000/mm3 
5 31/M 3 47,XY,+8[15]/46,XY,t(9;22)(q32;q12)[10] 16000/mm3 
6 33/M 3 47,XY,+8[12]/46,XY,t(9;22)(q32;q12)[08] 19000/mm3 
7 48/M 3.5 45,X,-Y, t(9;22)(q34;q11)  20000/mm3 
8 52/M 3 52,XYY,del(2p),+der(9)add(9q)×2,+14,+17,+20,+der(22)del(22q)×2 
 
29000/mm3 
9 36/F 2.5 45,XX,-7,t(9;22)(q32;q12)  54000/mm3 
10 49/F 2 45,XX,-7,t(9;22)(q32;q12)[16]/45,XX,-7[06]/46,XX,t(9;22) (q34;q12)[4] 48000/mm3 
11 36/F 2.5 45,XX,-10,-13,+mar/46,XX,9q+,+mar/46,XX,t(9;22)(q34;q12)/46,XX  
(1:3:21:10)   
26000/mm3 
12 36/M 3 48,XY,+8,t(9;22)(q34;q12),+19  28000/mm3 
13 34/F 3 47,XX,+6/46,XX,t(9;22) )(q34;q12)/48,XX,+6,+8,t(9;22) (q34;q12) 35000/mm3 
14 56/F 3 68,XXX, der(9)add (9q)X2,-17,iso(17)(q11.2) , +der(22)del(22q)X2   33000/mm3 
15 72/M 3.6 46,XY/47,XY,t(9;22)(q34;q11),+mar 31500/mm3 
16 29/M 3 47,XY,t(9;22) )(q34;q12)/46,XY,Iso(17q)  22000/mm3 
17 31/M 3 47,XY,t(9;22) )(q34;q12)/46,XY,Iso(17q) 19500/mm3 
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Four individuals were having complex three ways translocation along with some secondary abnormality 
at the time of diagnosis (Fig.2a&3a) (Table 2). They were given Imatinib 400 mg/ day for 6 month but they 
failed to achieve CHR, CCyR and MMR. Then the dose was increased by 600mg/day for another 5-6 
months where partial hematological remission (PHR) was achieved with approximately 85-90% Ph+ cells. 
Involvement of other chromosome in this complex translocation could be a  probable reason for Imatinib 
resistance or prolong imatinib response [7]. 
 
Figure  2a    46,XY,t(6;9;22) (p22;q34;q12)        
 
 
 
 
 
 
 
 
 
 
                          Figure 2b  signal pattern   1F2R2G  : which suggest variant (three or four way translocation) 
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Table 2  Cytogenetic and hematological findings in patient with primary resistance to imatinib 
 
Sr 
no 
Age/sex Years on 
Imatinib 
Cytogenetic  study Total WBC 
count 
1 33/M 1.2 46,XY,t(3;9;22)(q26;q34;q12) 72000/mm3 
2 34/F 1.6 46,XX,t(6;9;22) (P22;q34;q12) 92000/mm3 
3 41/M 1.6 46,XY.-3,+8,t(9;22;16)(q34;q11.2;p12),+14,-15,+17,-19,-21,+der(22)del(22q)   10000/mm3 
4 37/F 1.8 45,XX,del(5q)(q22),t(9;22)(q34;q12) 120000/mm3 
 
 
 
  
 
 
 
                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3a   46,XY,-3,+8,t(9;22;16)(q34;q11.2;p12),+14,-15,+17,-19,-21,+der(22)t(9;22)(q34;q11.2) 
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Figure 3b signal pattern 2F2R2G 
 
The incident of both typical and atypical BCR/ABL gene rearrangement was observed when we perform 
FISH (Fluorescence In Situ Hybridization) by using BCR/ABL dual colour dual fusion probe (Kreatech 
diagnostics,  The Netherlands).  Majority of individuals shows typical signal pattern of DF-FISH, 
2F1R1G, while few shows 4F1R1G signal pattern (Fig.1b) which is an indication of extra Ph+ 
chromosome. Atypical signal pattern of 1F2R2G (Fig.2b) and 2F2R2G (Fig.3b) was also observed in 3 
individual which indicates complex translocation with additional partner along with extra Ph+. 
Molecular monitoring of the BCR-ABL transcript in chronic myeloid leukemia (CML) using 
quantitative RT-PCR provides important diagnostic and prognostic information.Karyotyping, FISH, 
and real-time PCR give reliable results but differences due to measurement of altered target structures 
have to be kept in mind when using these data for definition of remission status. Correlations between 
all methods applied were highly significant. Conventional RT-PCR measure BCR-ABL transcripts on 
the m-RNA level and are therefore dependent on the transcription rate of BCR-ABL. Despite the fact 
that chromosome analysis, FISH, and RT-PCR measure BCR-ABL positivity on different biological 
levels and is dependent on different parameters. In the vast majority of CML patients, and in up to 
35% of Philadelphia chromosome-positive precursor B-ALL, the breakpoint on chromosome 22 is 
located between exons 12 and 16 (b1 to b5) of the BCR gene, in the major breakpoint cluster region 
(M-bcr). The M-bcr transcription product has two junctional variants, b2a2 and b3a2 that give rise to 
the BCR/ABL1 chimeric protein p210, a deregulated tyrosine kinase. In a small minority of CML 
patients and in a majority of patients with Philadelphia chromosome positive precursor B-ALL, there 
is a minor breakpoint region giving rise to junctional variant e1a2, which codes for the BCR/ABL1 
chimeric protein p190 [8]. 
The breakpoints within the ABL1 take place either upstream of exon Ib, downstream of exon Ia, or, 
more frequently, between exons Ib and Ia [9]. In most patients with CML and in one-third of those 
with Ph-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL) the breakpoints within BCR map 
to a 5.8-kilobase (kb) area spanning exons e12-e16 (formerly called b1-b5), referred to as the major 
breakpoint cluster region (M-bcr). Alternative splicing gives rise to fusion transcripts with either b2a2 
or b3a2 junctions that generate a 210-kDa protein (p210BCR-ABL1) [10]. There is controversy in the 
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literature about the use of peripheral blood and bone marrow for the monitoring of BCR/ABL1 level in 
chronic myeloid leukemia. The differences and correlations of BCR-ABL mRNA between peripheral 
blood (PB) and bone marrow (BM) assays  depends on the depth of the molecular response in BM for 
CML during imatinib therapy [11], whereas few  study suggest that peripheral blood is in concordant 
with bone marrow and can be used to monitor the disease [12]. In the present study we also found no 
difference in the use of peripheral blood and bone marrow in the monitoring of disease and remission. 
Variant Philadelphia (Ph) chromosome translocations have been reported in 5%-10% of patients with 
newly diagnosed chronic myeloid leukemia (CML) [13]. Variant translocations may involve one or 
more chromosomes in addition to 9 and 22. Presence of variant translocations has no impact on the 
cytogenetic and molecular response or on outcome, regardless of the involvement of different 
mechanisms [14-16], however, in the present study, when BCR/ABL1 transcript was performed in 
patient with complex translocation; we observed Minimum molecular remission (MMR) to imatinib 
instead of complete molecular remission. A point mutation in the BCR/ABL1 transcript could be a one 
of the reason for these MMR in patient with complex translocation and analysis of such mutation in 
BCR/ABL1 transcript will help to monitor effect of imatinib and remission.   
Patients can be classified (Table 3) according to their response to treatment, which can be considered 
optimal, suboptimal, or failure [17, 18]. Failure indicates that primary resistance patients in this category 
should be switched to another treatment. Patients in the suboptimal category may still benefit from 
continued treatment with Imatinib, but a favorable long-term outcome is not probable at the current dose. 
Resistance to Imatinib may be due to other genes involved along with BCR-ABL fusion or point mutation 
in the BCR-ABL kinase domain. To date, more than 50 different BCR-ABL kinase domain mutations have 
been found to be associated with Imatinib resistance
 
[19, 20]. A point mutation in BCR-ABL kinase domain 
can cause an amino acid change, which impairs the critical contact points of Imatinib binding or alters the 
conformation of the protein. BCR-ABL1 mutation analysis is recommended to facilitate selection of 
appropriate therapy for patients with chronic myeloid leukaemia after treatment with imatinib has failed, 
since some frequently occurring mutations confer clinical resistance to nilotinib and/or dasatinib [ 21]. 
 
Table 3 Operational Definition of Failure and Suboptimal Response for Previously Untreated Patients in Early 
Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib 400 mg/day 
 
Time After Diagnosis     
    (months) 
Failure Suboptimal Response 
3 No HR (stable disease or disease 
progression) 
Less than CHR 
6 Less than CHR, no CyR (Ph+ >95%) Less than PCyR (Ph+ >35%) 
12 Less than PCyR (Ph+ >35%) Less than CCyR 
18 Less than CCyR Less than MMR 
Anytime Loss of CHR, loss of CCyR, mutation ACA in Ph+ cells, loss of MMR, 
mutation 
ACA=additional chromosome abnormalities; CHR=complete hematologic response; CCyR=cytogenetic 
response; HR=hematologic response; MMR=major molecular response; PCyR=partial CyR; Ph+=Philadelphia 
chromosome positive. 
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Trisomy 8 and iso(17q) are most commonly involved as a secondary abnormality in CML. Controversial 
studies found in the literature regarding additional chromosomal abnormality and survival or therapeutic 
response in chronic phase. Various secondary chromosome abnormalities and multiple clones results in 
shorter survival in CML patients [22]. The prognostic significance of the secondary genetic changes is not 
uniform, although abnormalities involving chromosome 17, e.g., i(17q), have repeatedly been shown to be  
ominous additional cytogenetic and molecular genetic aberrations is most likely modified by the treatment 
modalities used [23]. 
Conclusion 
Chromosome analysis is still the gold standard for diagnosis and follow-up studies in CML. Especially in 
good responder’s sensitivity of chromosome analysis are too low to detect residual disease. Periodic (every 
6–12 months) cytogenetic monitoring for karyotypic abnormalities is critical throughout imatinib therapy to 
detect clonal evolution even in cases of early CCR. In the present study we found primary resistance to 
imatinib in 4 CML diagnosed individuals who had complex chromosomal rearrangement, despite low 
numbers, in our experience patients carrying complex Ph+ translocations do differ significantly in 
hematological and clinical features from those with standard translocation. while CML relapse were 
observed in 17 individuals with involvement of other chromosomes along with Ph+, further we observed 
that 3 patients out of this 17 were irregular in the uptake of Imatinib after achieving CHR and CCyR after 
12-14 months of therapy with imatinib, so secondary abnormality and irregularity in uptake of imatinib 
could be a reason for relapse and resistance to Imatinib. Detection of BCR-ABL mutants prior to and 
during the course of Imatinib therapy may aid in risk stratification as well as in determining therapeutic 
strategies.   
Imatinib dose escalation may be considered in some patients who experience a loss of response on 400 
mg/day Imatinib or in those with low Imatinib plasma levels. Treatment should be changed to Dasatinib or 
Nilotinib if a response is lost in patients who received higher doses of Imatinib (i.e., 600–800 mg/day) or if 
Imatinib-resistant mutations emerge however data about the outcome of patients with variant translocations 
after therapy with next generation tyrosine kinase inhibitors are limited.  
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